Nutritional Growth Solutions Ltd. has received positive results from open extension (6-12 months) clinical trial on its Grow Daily Boys 10+ formula. Following six months of double-blinded intervention with nutritional formula or placebo, an open-label extension phase was carried out for another six months. In the extension phase Grow Daily Boys 10+ was provided to all the participants in both the intervention and placebo arms. Seventy-nine healthy, lean, and short, pre-adolescent ten to 14.5-year-old males completed the extension phase.

The extension phase results found significant dose-response correlations between the consumption of Grow Daily Boys 10+ and the gain in height, weight, and muscle-mass. Throughout the study, net changes in fat mass and fat mass percentage were minor (mean changes of less than 0.8 kg and less than 0.8%, respectively), showing the intervention had no obesogenic effect. Participants who consumed at least 50% of the recommended daily dose of Grow Daily Boys 10+ for either six or 12 months maintained their average height increase rate throughout the year, while poor consumers (who consumed less than 50%) displayed a decrease in growth rate.

Highlights: Positive open extension phase (6-12 months) clinical trial results for Healthy Heights® Grow Daily Boys 10+ to assess effect on height, weight, and body composition in healthy, lean, and short pre-adolescent 10 to 14.5-year-old males. Results found significant dose-response correlations between the consumption of Grow Daily Boys 10+ and the gain in height, weight, and muscle-mass. Throughout the study, the net changes in fat mass percentage were minor, supporting the safety of the intervention in terms of a possible obesogenic effect.

Participants who consumed at least 50% of the recommended daily dose of Grow Daily Boys 10+ for either 6 or 12 months maintained their average height increase rate throughout the study period, while those who consumed less than 50% displayed a decrease in growth rate. Results of the second six-month phase of a 12-month, randomised, double-blind, placebo-controlled study in peer-reviewed medical journal Hormone Research in Pediatrics 1 Clinical study with a formulation tailored for girls is ongoing.